Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Plexxikon, Inc.
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Deal snapshot: Viewing antibody-drug conjugates as a key to growing its cancer franchise beyond Keytruda, Merck & Co. will partner with C4 to develop protein degrader-antibody conjugates for cancer.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.
Drug Discovery Technologies
- Drug Discovery Technologies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.